免疫联合化疗治疗晚期非小细胞肺癌的疗效及机体淋巴细胞变化的相关分析

Correlative analysis of the efficacy of immune combined with chemotherapy in the treatment of advanced non-small cell lung cancer and the changes of lymphocytes in the body

目的观察并比较晚期非小细胞肺癌患者应用免疫联合化疗与单用化疗的疗效和治疗前后机体淋巴细胞数目的变化,为晚期非小细胞肺癌的治疗提供循证医学证据。方法选取2018年1月~2020年1月在潍坊市人民医院经病理确诊为晚期非小细胞肺癌的患者共40例,按1∶1分为实验组和对照组,实验组应用免疫联合化疗,对照组单用化疗。分析比较这两种方案的疗效,并通过测定淋巴细胞亚群分析治疗前后淋巴细胞数目变化。结果 ①实验组治疗总有效率为85.00%,显著高于对照组的55.00%,差异有统计学意义(P<0.05)。②对比实验组和对照组CD8+、CD4+、CD4+/CD8+水平,治疗前两组差异无统计学意义(P>0.05);而治疗后实验组明显优于对照组,差异有统计学意义(P<0.05)。结论免疫联合化疗对比单用化疗治疗晚期非小细胞肺癌患者,可明显改善机体免疫功能,进一步提高疗效。

Objective To investigate and compare the efficacy of immune combined chemotherapy and chemotherapy alone and the number of lymphocytes in patients with advanced non-small cell lung cancer before and after treatment.To provide evidence-based medical evidence for the treatment of advanced non-small cell lung cancer.Methods Forty patients with advanced non-small cell lung cancer diagnosed pathologically in Weifang People’s Hospital from January 2018 to January 2020 were divided into experimental group and control group according to 1∶1.The combination of immunotherapy and chemotherapy was used in the experimental group.The control group was treated with chemotherapy alone.The efficacy of these two regimens were compared and analyzed, and changes of lymphocyte number before and after treatment were analyzed by measuring lymphocyte subsets.Results①The total effective rate of treatment in the experimental group was 85.00%,which was significantly higher than 55.00% in the control group, and the difference was statistically significant(P<0.05).②The CD8+,CD4+,CD4+/CD8+ levels between the experimental group and the control group were compared.There was no significant difference between the two groups before treatment(P>0.05).The experimental group was significantly better than the control group after treatment, and the difference was statistically significant(P<0.05).Conclusion Immunotherapy combined with chemotherapy compared with chemotherapy alone for patients with advanced non-small cell lung cancer can significantly improve the body’s immune function and further improve the efficacy.